Diagnosing Frontotemporal Lobar Degeneration

Brief Title

Diagnosing Frontotemporal Lobar Degeneration

Official Title

Multimodal Assessment For Predicting Specific Pathological Substrate in Frontotemporal Lobar Degeneration

Brief Summary

      To establish diagnostic tools to make an accurate clinical and pathological diagnosis of
      patients with clinical FTLD syndromes
    

Detailed Description

      The goal of this study is to determine the best diagnostic test for diagnosing frontotemporal
      lobar degeneration. To accomplish this, the current study will evaluate different tests:
      brain imaging, skin biopsy, body fluid samples (blood and cerebrospinal fluid), thinking
      abilities, everyday functioning, and brain autopsy. The study team hopes that this
      information can be used to guide diagnosis and further understanding of mechanism of disease
      in Frontotemporal Lobar Degeneration and possibly treatment in the future.
    

Study Type

Observational

Primary Outcome

Structural and Functional Diffferences between the FTLD groups via MRI of the brain

Condition

Corticobasal Syndrome

Intervention

Observational Study

Study Arms / Comparison Groups

 Progressive supranuclear palsy

Description:  Observational Study

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Status

Other

Estimated Enrollment

100

Start Date

August 2015

Completion Date

December 2019

Primary Completion Date

December 2019

Eligibility Criteria

        Inclusion Criteria:

          -  Participant must have a reliable study partner who can provide an independent
             evaluation of functioning.

          -  Able to read, understand and speak English for neuropsychological testing.

          -  All subjects must meet one of these diagnostic criteria (A) probable behavioral
             variant FTD, (B) MRI-supported non-fluent variant PPA; (C) MRI-supported semantic
             variant PPA and [18F]T807 negative (D) probable CBS: using current criteria for
             CBS(27); (E) PSP: inclusion criteria for PSP are based upon the National Institute of
             Neurological Disorders and Stroke Society of Progressive Supranuclear Palsy
             (NINDS-SPSP) (F) FTD-MND

          -  Control subjects must have a normal neurological exam, a CDR sum of boxes = 0, and
             MMSE score equal to or greater than 28

        Exclusion Criteria:

          -  Patients with clinical, imaging or CSF A beta/ tau profile consistent with AD

          -  History of traumatic brain injury, brain tumors, stroke or other neurological or
             psychiatric disorders that can explain symptoms will be excluded.

          -  Premenopausal women will be asked to consent to a pregnancy test prior to each scan as
             pregnant women will be excluded from study because of potential harm to fetus from PET
             study.

          -  Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal
             fragments or foreign objects in the eyes, skin or body.
      

Gender

All

Ages

18 Years - 90 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Maria C Tartaglia, M.D., 416-507-6880, [email protected]

Location Countries

Canada

Location Countries

Canada

NCT ID

NCT02964637

Organization ID

14-8398-A

Responsible Party

Principal Investigator

Study Sponsor

University Health Network, Toronto

Study Sponsor

Maria C Tartaglia, M.D., Principal Investigator, Toronto Western Hospital, UHN; Tanz CRND

Verification Date

April 2019